Activated protein C, protease activated receptor 1, and neuroprotection.
暂无分享,去创建一个
[1] Zijian Li,et al. New Insights into Modes of GPCR Activation. , 2018, Trends in pharmacological sciences.
[2] José A Fernández,et al. PAR1 biased signaling is required for activated protein C in vivo benefits in sepsis and stroke. , 2018, Blood.
[3] P. Zheng,et al. Suppression of NLRP3 attenuates hemorrhagic transformation after delayed rtPA treatment in thromboembolic stroke rats: Involvement of neutrophil recruitment , 2018, Brain Research Bulletin.
[4] Sudarshan Rajagopal,et al. Biased signalling: from simple switches to allosteric microprocessors , 2018, Nature Reviews Drug Discovery.
[5] Vsevolod V. Gurevich,et al. Molecular Mechanisms of GPCR Signaling: A Structural Perspective , 2017, International journal of molecular sciences.
[6] C. Esmon,et al. Cytoprotective activated protein C averts Nlrp3 inflammasome-induced ischemia-reperfusion injury via mTORC1 inhibition. , 2017, Blood.
[7] Mohit Kumar,et al. Novel Structural Insights into GPCR-β-Arrestin Interaction and Signaling. , 2017, Trends in cell biology.
[8] R. Medcalf. Fibrinolysis: from blood to the brain , 2017, Journal of thrombosis and haemostasis : JTH.
[9] J. Griffin,et al. Can adjunctive therapies augment the efficacy of endovascular thrombolysis? A potential role for activated protein C , 2017, Neuropharmacology.
[10] R. Flaumenhaft,et al. Targeting PAR1: Now What? , 2017, Trends in pharmacological sciences.
[11] B. Isermann. Homeostatic effects of coagulation protease‐dependent signaling and protease activated receptors , 2017, Journal of thrombosis and haemostasis : JTH.
[12] E. Kiseleva,et al. A new concept of action of hemostatic proteases on inflammation, neurotoxicity, and tissue regeneration , 2017, Biochemistry (Moscow).
[13] C. Jackson,et al. Activated protein C binds directly to Tie2: possible beneficial effects on endothelial barrier function , 2017, Cellular and Molecular Life Sciences.
[14] Laura D. Healy,et al. Activated protein C inhibits neutrophil extracellular trap formation in vitro and activation in vivo , 2017, The Journal of Biological Chemistry.
[15] T. Arumugam,et al. Evidence that NF-κB and MAPK Signaling Promotes NLRP Inflammasome Activation in Neurons Following Ischemic Stroke , 2017, Molecular Neurobiology.
[16] J. Trejo,et al. Challenges and Opportunities in Protease-Activated Receptor Drug Development. , 2017, Annual review of pharmacology and toxicology.
[17] José A Fernández,et al. 2016 Scientific Sessions Sol Sherry Distinguished Lecturer in Thrombosis: Thrombotic Stroke: Neuroprotective Therapy by Recombinant-Activated Protein C. , 2016, Arteriosclerosis, thrombosis, and vascular biology.
[18] A. Ardeshirylajimi,et al. Occupancy of human EPCR by protein C induces β-arrestin-2 biased PAR1 signaling by both APC and thrombin. , 2016, Blood.
[19] S. Goldman,et al. 3K3A–activated protein C stimulates postischemic neuronal repair by human neural stem cells in mice , 2016, Nature Medicine.
[20] A. McConnachie,et al. Human neural stem cells in patients with chronic ischaemic stroke (PISCES): a phase 1, first-in-man study , 2016, The Lancet.
[21] Wusheng Zhu,et al. NLRP3 Is Involved in Ischemia/Reperfusion Injury. , 2016, CNS & neurological disorders drug targets.
[22] M. Nieman. Protease-activated receptors in hemostasis. , 2016, Blood.
[23] Ryan T. Strachan,et al. Conformationally Selective RNA Aptamers Allosterically Modulate the β2-Adrenoceptor , 2016, Nature chemical biology.
[24] José A Fernández,et al. Activated protein C promotes neuroprotection: mechanisms and translation to the clinic. , 2016, Thrombosis research.
[25] L. Bohn,et al. Biased agonism: An emerging paradigm in GPCR drug discovery. , 2016, Bioorganic & medicinal chemistry letters.
[26] J. Levy,et al. Concentration-Dependent Dual Role of Thrombin in Protection of Cultured Rat Cortical Neurons , 2015, Neurochemical Research.
[27] P. Walsh,et al. Activated protein C β-glycoform promotes enhanced noncanonical PAR1 proteolysis and superior resistance to ischemic injury. , 2015, Blood.
[28] J. O’Donnell,et al. Engineering activated protein C to maximize therapeutic efficacy. , 2015, Biochemical Society transactions.
[29] Paul M. George,et al. Novel Stroke Therapeutics: Unraveling Stroke Pathophysiology and Its Impact on Clinical Treatments , 2015, Neuron.
[30] J. Griffin,et al. Activated protein C: biased for translation. , 2015, Blood.
[31] F. Stavenuiter,et al. Noncanonical PAR3 activation by factor Xa identifies a novel pathway for Tie2 activation and stabilization of vascular integrity. , 2014, Blood.
[32] A. Rezaie. Protease-activated receptor signalling by coagulation proteases in endothelial cells , 2014, Thrombosis and Haemostasis.
[33] D. Hermann,et al. Stem cell therapies in preclinical models of stroke associated with aging , 2014, Front. Cell. Neurosci..
[34] H. Yim,et al. Efficacy and Safety of Stem Cell Therapies for Patients with Stroke: a Systematic Review and Single Arm Meta-Analysis , 2014, International journal of stem cells.
[35] J. Griffin,et al. Cytoprotective-selective activated protein C therapy for ischaemic stroke , 2014, Thrombosis and Haemostasis.
[36] C. Esmon,et al. Endothelial cell protein C receptor: a multiliganded and multifunctional receptor. , 2014, Blood.
[37] Ling Wei,et al. Cell based therapies for ischemic stroke: From basic science to bedside , 2014, Progress in Neurobiology.
[38] J. Griffin,et al. Phase 1 safety, tolerability and pharmacokinetics of 3K3A-APC in healthy adult volunteers. , 2014, Current pharmaceutical design.
[39] C. Power,et al. Inflammasomes in the CNS , 2014, Nature Reviews Neuroscience.
[40] G. Steinberg,et al. Stem cell therapy for acute cerebral injury: what do we know and what will the future bring? , 2013, Current opinion in neurology.
[41] L. O. Mosnier,et al. Novel mechanisms for activated protein C cytoprotective activities involving noncanonical activation of protease-activated receptor 3. , 2013, Blood.
[42] S. Savitz. Cell therapies: careful translation from animals to patients. , 2013, Stroke.
[43] T. Hara,et al. Protein C deficiency as the major cause of thrombophilias in childhood , 2013, Pediatrics international : official journal of the Japan Pediatric Society.
[44] S. Goldman,et al. An Activated Protein C Analog Stimulates Neuronal Production by Human Neural Progenitor Cells via a PAR1-PAR3-S1PR1-Akt Pathway , 2013, The Journal of Neuroscience.
[45] N. Tajiri,et al. Stem Cell Transplantation for Neuroprotection in Stroke , 2013, Brain sciences.
[46] J. Griffin,et al. Biased agonism of protease-activated receptor 1 by activated protein C caused by noncanonical cleavage at Arg46. , 2012, Blood.
[47] Patricia D. Williams,et al. Preclinical safety and pharmacokinetic profile of 3K3A-APC, a novel, modified activated protein C for ischemic stroke. , 2012, Current pharmaceutical design.
[48] D. Howells,et al. Stem Cell-Based Therapy for Experimental Stroke: A Systematic Review and Meta-Analysis , 2012, International journal of stroke : official journal of the International Stroke Society.
[49] Eric Boerwinkle,et al. Associations Between Lipoprotein(a) Levels and Cardiovascular Outcomes in Black and White Subjects: The Atherosclerosis Risk in Communities (ARIC) Study , 2011, Circulation.
[50] J. Trejo,et al. Activated protein C promotes protease-activated receptor-1 cytoprotective signaling through β-arrestin and dishevelled-2 scaffolds , 2011, Proceedings of the National Academy of Sciences.
[51] A. Kuliopulos,et al. Matrix metalloproteases and PAR1 activation. , 2011, Blood.
[52] A. Rezaie. The occupancy of endothelial protein C receptor by its ligand modulates the par‐1 dependent signaling specificity of coagulation proteases , 2011, IUBMB life.
[53] J. Griffin,et al. Cytoprotective protein C pathways and implications for stroke and neurological disorders , 2011, Trends in Neurosciences.
[54] K. Khair,et al. Purpura fulminans: recognition, diagnosis and management , 2011, Archives of Disease in Childhood.
[55] S. Julovi,et al. Activated Protein C Enhances Human Keratinocyte Barrier Integrity via Sequential Activation of Epidermal Growth Factor Receptor and Tie2* , 2010, The Journal of Biological Chemistry.
[56] A. Rezaie. Regulation of the protein C anticoagulant and antiinflammatory pathways. , 2010, Current medicinal chemistry.
[57] F. Castellino,et al. The efficacy of activated protein C in murine endotoxemia is dependent on integrin CD11b. , 2010, The Journal of clinical investigation.
[58] Keshava Rajagopal,et al. Teaching old receptors new tricks: biasing seven-transmembrane receptors , 2010, Nature Reviews Drug Discovery.
[59] K. Fukudome,et al. Activated protein C utilizes the angiopoietin/Tie2 axis to promote endothelial barrier function , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[60] José A Fernández,et al. Hyperantithrombotic, noncytoprotective Glu149Ala-activated protein C mutant. , 2009, Blood.
[61] A. Ayala,et al. Recombinant human activated protein C inhibits integrin-mediated neutrophil migration. , 2009, Blood.
[62] J. Trejo,et al. Caveolae are required for protease-selective signaling by protease-activated receptor–1 , 2009, Proceedings of the National Academy of Sciences.
[63] José A Fernández,et al. Neuroprotective activities of activated protein C mutant with reduced anticoagulant activity , 2009, The European journal of neuroscience.
[64] Hiroshi Deguchi,et al. Activated protein C ligation of ApoER2 (LRP8) causes Dab1-dependent signaling in U937 cells , 2009, Proceedings of the National Academy of Sciences.
[65] R. Deane,et al. Endothelial Protein C Receptor-Assisted Transport of Activated Protein C across the Mouse Blood—Brain Barrier , 2009, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[66] José A Fernández,et al. Activated Protein C Promotes Neovascularization and Neurogenesis in Postischemic Brain via Protease-Activated Receptor 1 , 2008, The Journal of Neuroscience.
[67] M. Manco‐Johnson,et al. Protein C deficiency , 2008, Haemophilia : the official journal of the World Federation of Hemophilia.
[68] A. Marchese,et al. G protein-coupled receptor sorting to endosomes and lysosomes. , 2008, Annual review of pharmacology and toxicology.
[69] J. Griffin,et al. Activated Protein C Mutant with Minimal Anticoagulant Activity, Normal Cytoprotective Activity, and Preservation of Thrombin Activable Fibrinolysis Inhibitor-dependent Cytoprotective Functions* , 2007, Journal of Biological Chemistry.
[70] A. Malik,et al. Protease-activated receptor-3 (PAR3) regulates PAR1 signaling by receptor dimerization , 2007, Proceedings of the National Academy of Sciences.
[71] J. Bae,et al. Engineering a Disulfide Bond to Stabilize the Calcium-binding Loop of Activated Protein C Eliminates Its Anticoagulant but Not Its Protective Signaling Properties* , 2007, Journal of Biological Chemistry.
[72] J. Bae,et al. Receptors of the protein C activation and activated protein C signaling pathways are colocalized in lipid rafts of endothelial cells , 2007, Proceedings of the National Academy of Sciences.
[73] José A Fernández,et al. Activated protein C inhibits tissue plasminogen activator–induced brain hemorrhage , 2006, Nature Medicine.
[74] E. Di Cera,et al. Protective Signaling by Activated Protein C Is Mechanistically Linked to Protein C Activation on Endothelial Cells* , 2006, Journal of Biological Chemistry.
[75] W. Ruf,et al. Protease-activated Receptor-1 Signaling by Activated Protein C in Cytokine-perturbed Endothelial Cells Is Distinct from Thrombin Signaling* , 2005, Journal of Biological Chemistry.
[76] José A Fernández,et al. Tissue plasminogen activator neurovascular toxicity is controlled by activated protein C , 2004, Nature Medicine.
[77] José A Fernández,et al. Activated protein C and ischemic stroke , 2004, Critical care medicine.
[78] José A Fernández,et al. Activated Protein C Prevents Neuronal Apoptosis via Protease Activated Receptors 1 and 3 , 2004, Neuron.
[79] C. Esmon. The protein C pathway. , 2003, Critical care medicine.
[80] J. Griffin,et al. Inhibition of staurosporine-induced apoptosis of endothelial cells by activated protein C requires protease-activated receptor-1 and endothelial cell protein C receptor. , 2003, The Biochemical journal.
[81] O. Benzakour,et al. Activated protein C alters cytosolic calcium flux in human brain endothelium via binding to endothelial protein C receptor and activation of protease activated receptor-1. , 2003, Blood.
[82] José A Fernández,et al. Recombinant murine-activated protein C is neuroprotective in a murine ischemic stroke model. , 2003, Blood cells, molecules & diseases.
[83] José A Fernández,et al. Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective , 2003, Nature Medicine.
[84] J. Griffin,et al. Molecular Characterization of an Extended Binding Site for Coagulation Factor Va in the Positive Exosite of Activated Protein C* , 2002, The Journal of Biological Chemistry.
[85] W. Ruf,et al. Activation of Endothelial Cell Protease Activated Receptor 1 by the Protein C Pathway , 2002, Science.
[86] U. Seligsohn,et al. Genetic susceptibility to venous thrombosis. , 2001, The New England journal of medicine.
[87] L. Gelbert,et al. Gene Expression Profile of Antithrombotic Protein C Defines New Mechanisms Modulating Inflammation and Apoptosis* , 2001, The Journal of Biological Chemistry.
[88] Berislav V. Zlokovic,et al. Anti-Inflammatory, Antithrombotic, and Neuroprotective Effects of Activated Protein C in a Murine Model of Focal Ischemic Stroke , 2001, Circulation.
[89] L. Brass,et al. Protease activated receptors: theme and variations , 2001, Oncogene.
[90] S. Coughlin,et al. Thrombin signalling and protease-activated receptors , 2000, Nature.
[91] S. Coughlin,et al. How the protease thrombin talks to cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[92] A. Folsom,et al. Prospective study of markers of hemostatic function with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. , 1999, Circulation.
[93] S. Coughlin,et al. Shutoff and agonist-triggered internalization of protease-activated receptor 1 can be separated by mutation of putative phosphorylation sites in the cytoplasmic tail. , 1999, Biochemistry.
[94] José A Fernández,et al. Brain-specific protein C activation during carotid artery occlusion in humans. , 1999, Stroke.
[95] Robert V Farese,et al. A dual thrombin receptor system for platelet activation , 1998, Nature.
[96] Scott R. Presnell,et al. Cloning and characterization of human protease-activated receptor 4. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[97] S. Coughlin,et al. Protease-activated receptor 3 is a second thrombin receptor in humans , 1997, Nature.
[98] José A Fernández,et al. Impairments of the protein C system and fibrinolysis in infection-associated stroke. , 1996, Stroke.
[99] B. Strömbeck,et al. Molecular cloning and functional expression of the gene encoding the human proteinase-activated receptor 2. , 1995, European journal of biochemistry.
[100] J. Hoxie,et al. Internalization and recycling of activated thrombin receptors. , 1993, The Journal of biological chemistry.
[101] V. Wheaton,et al. Tethered ligand agonist peptides. Structural requirements for thrombin receptor activation reveal mechanism of proteolytic unmasking of agonist function. , 1992, The Journal of biological chemistry.
[102] C. Esmon,et al. The region of the thrombin receptor resembling hirudin binds to thrombin and alters enzyme specificity. , 1991, The Journal of biological chemistry.
[103] V. Wheaton,et al. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation , 1991, Cell.
[104] A. Chang,et al. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. , 1987, The Journal of clinical investigation.
[105] J. Katz,et al. INHERITED PROTEIN C DEFICIENCY AND COUMARIN-RESPONSIVE CHRONIC RELAPSING PURPURA FULMINANS IN A NEWBORN INFANT , 1983, The Lancet.
[106] Greiner Ac,et al. Schizophrenia-melanosis: cause or side-effect? , 1965 .
[107] B. Kobilka,et al. Structure and dynamics of GPCR signaling complexes , 2017, Nature Structural & Molecular Biology.
[108] J. Griffin,et al. bloodjournal.hematologylibrary.org at PENN STATE UNIVERSITY on February 21, 2013. For personal use only. The cytoprotective protein C pathway , 2006 .
[109] J. Griffin,et al. Activated protein C variants with normal cytoprotective but reduced anticoagulant activity. , 2004, Blood.
[110] D. Wagner,et al. Hemostasis, Thrombosis, and Vascular Biology , 2003 .